-
-
-
-
-
-
-
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
-
-
-
-
-
-
-
Takeda (TAK) Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection
-
-
-
71,482 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

